Novakand Pharma AB (publ) (ST:LARK) — Stock Price
Novakand Pharma AB (publ) (ST:LARK) is currently trading at Skr2.24 SEK, up 3.23% today. Over the past 52 weeks, shares have ranged between Skr1.84 and Skr2.56. This page tracks Novakand Pharma AB (publ)'s live share price on the ST exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market value of Novakand Pharma AB (publ).
Novakand Pharma AB (publ) (LARK) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Novakand Pharma AB (publ)'s daily closing share price and trading volume on the ST exchange over the past year, giving a clear view of recent price momentum and liquidity.
Novakand Pharma AB (publ) Income Statement — Revenue, Profit & Earnings by Year
Novakand Pharma AB (publ)'s annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | Skr0.00 | Skr326.00K | Skr5.54 Million | Skr26.70 Million | Skr84.04 Million |
| Cost of Revenue | Skr8.16 Million | Skr47.11 Million | Skr26.84 Million | Skr45.90 Million | Skr68.88 Million |
| Gross Profit | Skr-8.16 Million | Skr-46.78 Million | Skr-21.29 Million | Skr-19.20 Million | Skr15.16 Million |
| Research & Development | — | — | — | — | — |
| SG&A | — | — | — | — | Skr54.59 Million |
| Total Operating Expenses | Skr4.81 Million | Skr31.25 Million | Skr18.77 Million | Skr3.11 Million | Skr15.59 Million |
| Operating Income | Skr-12.98 Million | Skr-47.22 Million | Skr-38.60 Million | Skr-6.95 Million | Skr20.96 Million |
| EBITDA | Skr-7.19 Million | Skr-34.22 Million | Skr-35.98 Million | Skr-5.86 Million | Skr23.56 Million |
| EBIT | Skr-12.98 Million | Skr-47.22 Million | Skr-36.31 Million | Skr-6.16 Million | Skr20.96 Million |
| Interest Expense | Skr83.00K | Skr0.00 | Skr4.80K | Skr1.68K | Skr0.00 |
| Income Before Tax | Skr-12.36 Million | Skr-44.88 Million | Skr-35.66 Million | Skr-6.16 Million | Skr20.96 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | Skr-12.36 Million | Skr-44.88 Million | Skr-35.66 Million | Skr-6.16 Million | Skr20.96 Million |
Novakand Pharma AB (publ) Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Novakand Pharma AB (publ)'s financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | Skr56.73 Million | Skr75.88 Million | Skr120.61 Million | Skr158.22 Million | Skr166.22 Million |
| Total Current Assets | Skr6.66 Million | Skr75.12 Million | Skr103.24 Million | Skr139.22 Million | Skr144.62 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | Skr3.25 Million | — | — | — | — |
| Net Receivables | Skr436.00K | — | Skr1.21 Million | Skr4.22 Million | Skr0.00 |
| Inventory | — | — | — | — | Skr0.00 |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | Skr0.00 | Skr12.62 Million | Skr14.92 Million | Skr17.21 Million |
| Total Liabilities | Skr1.24 Million | Skr4.30 Million | Skr4.16 Million | Skr6.10 Million | Skr7.94 Million |
| Total Current Liabilities | Skr1.24 Million | Skr4.30 Million | Skr4.16 Million | Skr6.10 Million | Skr7.94 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | Skr-2.59 Million | Skr-73.75 Million | Skr-101.44 Million | Skr-131.78 Million | Skr-136.74 Million |
| Total Stockholder Equity | Skr55.49 Million | Skr71.58 Million | Skr116.46 Million | Skr152.12 Million | Skr158.28 Million |
| Retained Earnings | Skr-111.33 Million | Skr-44.88 Million | Skr-108.66 Million | Skr-72.99 Million | Skr-66.83 Million |
Novakand Pharma AB (publ) Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Novakand Pharma AB (publ) generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | Skr-12.78 Million | Skr-29.95 Million | Skr-30.56 Million | Skr-16.67 Million | Skr22.11 Million |
| Capital Expenditures | Skr0.00 | Skr0.00 | Skr108.90K | Skr0.00 | Skr147.73K |
| Free Cash Flow | Skr-12.78 Million | Skr-29.95 Million | Skr-30.67 Million | Skr-16.67 Million | Skr21.97 Million |
| Investing Cash Flow | Skr-49.78 Million | Skr-81.00K | Skr-988.90K | — | Skr-147.73K |
| Financing Cash Flow | Skr-3.96 Million | — | — | — | Skr65.88 Million |
| Dividends Paid | Skr-3.96 Million | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | Skr0.00 | Skr2.10 Million | Skr329.34K | Skr2.59 Million | Skr2.59 Million |
| Change in Cash | Skr-66.52 Million | Skr-27.69 Million | Skr-30.33 Million | Skr-4.97 Million | Skr87.85 Million |
Novakand Pharma AB (publ) Earnings History — EPS Actual vs. Analyst Estimates
Track Novakand Pharma AB (publ)'s quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
Earnings history is not currently available for Novakand Pharma AB (publ).